cysteamine bitartrate

cysteamine bitartrate

an anticysteine that reacts with cystine in the cell lysosomes to convert it to cysteine and a mixed disulfide compound, which can then exit the lysosome in patients with a metabolic defect causing cystinosis.
indications It is prescribed in the treatment of an inherited amino acid metabolic disease in which cysteine accumulates in the cells and can lead to the formation of crystals that can damage various organs, especially the kidneys (nephropathic cystinosis).
contraindications It should not be given to patients with allergy to cysteamine or penicillamine, depression, drowsiness, lethargy, neurological disorders, or diseases of the liver or digestive tract.
adverse effects The side effects most often reported include vomiting, diarrhea, constipation, appetite loss, nausea, headaches, convulsions, and seizures.
Mentioned in ?
References in periodicals archive ?
PROCYSBI[R] is a delayed-release form of cysteamine bitartrate that can be used to manage cystinosis by continually reducing the toxic levels of cystine in the cells.
Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients.
Food and Drug Administration ("FDA") seeking approval to market its investigational drug candidate, Cysteamine Bitartrate Delayed- release Capsules (RP103), for the potential treatment of nephropathic cystinosis.
The tiny drug developer announced positive Phase 2a clinical trial results from its pilot study of delayed-release cysteamine bitartrate in 11 adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver disease believed to affect 5% to 11% of the U.
Nasdaq:RPTP) has announced that it has enrolled the first patient in a pivotal Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").
The conducted trial evaluated the safety and efficacy of RP103, or cysteamine bitartrate delayed-release capsules, in children with biopsy-confirmed NASH.
Medicine company Raptor Pharmaceutical Corp (NasdaqGM:RPTP) revealed on Monday the receipt of a key patent covering enteric-coated oral formulations of cysteamine bitartrate, including its proprietary microbead formulation, RP103, from the European Patent Office.
Medicine company Raptor Pharmaceutical Corp (Nasdaq:RPTP) announced on Friday the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) seeking approval to market its investigational drug candidate, Cysteamine Bitartrate Delayed-release Capsules (RP103), for the potential treatment of nephropathic cystinosis.
Medicine company Raptor Pharmaceutical Corp (NasdaqGM:RPTP) said on Wednesday that its New Drug Application (NDA) for its investigational drug candidate Cysteamine Bitartrate Delayed-release Capsules (RP103) has been accepted for filing.
Currently, Raptor plans to use proceeds from the ATM programme to support general corporate purposes, the commercial launch of its proprietary, delayed-release cysteamine bitartrate formulation RP103, for the potential treatment of nephropathic cystinosis and for the continued clinical development of RP103 in non-alcoholic steatohepatitis and Huntington's Disease.
8 June 2011 - US Raptor Pharmaceutical Corp (NASDAQ: RPTP) said on Monday that on 3 June the last clinical trial patient visits were completed and final data analysis will start this week on the Phase III study of its delayed-release oral formulation of cysteamine bitartrate in patients with nephropathic cystinosis.
15 February 2011 - US-based early development-stage Raptor Pharmaceutical Corp (NASDAQ: RPTP) today announced it has reopened enrollment in its Phase III clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate (DR Cysteamine) in patients with nephropathic cystinosis (cystinosis).